Shots:Leads Biolabs has granted Dianthus exclusive global rights to develop, manufacture, & commercialize LBL-047 as DNTH212 outside of Greater ChinaAs per the deal, Dianthus will get $20M upfront, $5M in Q4’25, & ~$13M in near-term milestones, with a total potential value of ~$1B incl. development, regulatory, & commercial milestones, plus tiered royalties from…
Shots:The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9BThe second quarter of the year also showcases multiple approvals of the therapies…

